These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37795433)

  • 1. The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports.
    Meng Y; Li X; Zhang L; Ye M
    Front Oncol; 2023; 13():1129629. PubMed ID: 37795433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma.
    Chen Y; Xu J; Zhang L; Song Y; Wen W; Lu J; Zhao Z; Kong W; Liu W; Guo A; Santarpia M; Yamada T; Cai X; Yu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):238-249. PubMed ID: 35280318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.
    Xu CW; Lei L; Wang WX; Lin L; Zhu YC; Wang H; Miao LY; Wang LP; Zhuang W; Fang MY; Lv TF; Song Y
    Transl Oncol; 2020 Sep; 13(9):100791. PubMed ID: 32492620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
    Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
    Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X
    BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC.
    Chang ZT; Chan TM; Wu CE
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.
    Xu H; Li W; Yang G; Li J; Yang L; Xu F; Yang Y; Ying J; Wang Y
    Target Oncol; 2020 Jun; 15(3):357-364. PubMed ID: 32418166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of
    Zhao C; Jiang T; Li J; Wang Y; Su C; Chen X; Ren S; Li X; Zhou C
    Transl Lung Cancer Res; 2020 Aug; 9(4):1149-1158. PubMed ID: 32953493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three Novel
    Li H; Yu T; Lin Y; Xie Y; Feng J; Huang M; Guo A; Liu X; Yin Z
    Onco Targets Ther; 2020; 13():7941-7948. PubMed ID: 32982275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR.
    Wu SG; Gow CH; Chen YL; Liu YN; Tsai MF; Shih JY
    Int J Cancer; 2023 Jul; 153(2):352-363. PubMed ID: 36912241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
    Huang LT; Zhang SL; Han CB; Ma JT
    Lung Cancer; 2022 Apr; 166():9-16. PubMed ID: 35151115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation.
    Chen J; Wu X; Wang J
    Front Oncol; 2022; 12():898586. PubMed ID: 35957876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent
    Qin Z; Zhang H; Yan P; Yu L; Hong C; Calvetti L; Passaro A; Araujo A; Chen Y
    J Thorac Dis; 2023 Jul; 15(7):4016-4026. PubMed ID: 37559636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR.
    Chung KP; Wu SG; Wu JY; Yang JC; Yu CJ; Wei PF; Shih JY; Yang PC
    Clin Cancer Res; 2012 Jun; 18(12):3470-7. PubMed ID: 22510346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.